1 link tagged with all of: alphafold + ai healthcare + drug discovery + daron acemoglu
Links
@DAcemogluMIT on X
MIT economist Daron Acemoglu argues that promised AI drug discovery gains have so far been thin, and that the US could improve health far more cheaply by redirecting some AI spending toward public health. He points to the US life expectancy gap with peer countries, which mostly reflects preventable deaths rather than a lack of new treatments.
- A Hill and Stein paper finds no evidence yet that applied drug development is targeting proteins whose structures AlphaFold predicted.
- Daphne Koller notes AI work is concentrated on the last layer of drug development (new molecules for known modalities), not on understanding new disease mechanisms, where data is scarce.
- Americans live about five years less than citizens of Switzerland, Sweden, Japan, and similar countries, mostly from deaths before 70 due to chronic disease, overdoses, and other preventable causes.
daron acemoglu
alphafold
drug discovery
ai healthcare